Q4 2024 saw 7% revenue growth and a near tripling of EBITDA, led by Human Health Ingredients, while Consumer Health Products declined but is expected to rebound in 2025. Restructuring and cost optimization are ongoing, with strong global demand and new product launches supporting future growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.